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AJH 2006; 19:1150–1155Background: The objective of this study was to test
whether baseline echocardiography in newly detected hy-
pertension improves left ventricular mass index and blood
pressure control. This is a randomized trial with primary
care patients.
Methods: After routine clinical work-up 177 consecu-
tive patients with newly detected hypertension were ran-
domized according to result of their echocardiogram (echo
group and control group). Treating physicians were en-
couraged to prescribe angiotensin II receptor antagonist
therapy for patients with evidence of hypertensive target
organ damage. Mean blood pressure (BP) and echocardio-
graphic left ventricular mass index were measured at base-
line and after 6 months of therapy in both groups.
Results: More patients with hypertensive target organ
damage were identified in the echo group as compared to
the control group (58 of 91 [64%] v 42 of 86 [49%]
land.
0895-7061/06/$32.00
doi:10.1016/j.amjhyper.2006.05.003patients (difference 15%, 95% CI 1%–29%). In the echo
group, 41 patients (45%) received angiotensin II receptor
antagonist therapy as compared to 27 patients (31%) in the
control group (difference 14%, 95% CI 0–28%). After 6
months, there were no differences in mean left ventricular
mass index, mean diastolic 24-h ambulatory BP monitor-
ing, or mean systolic and diastolic office BP between the
two groups.
Conclusions: In patients with newly detected hyper-
tension, baseline echocardiography detects more patients
with hypertensive target organ damage, but does not lead
to a reduction in left ventricular mass index or improved BP
control after 6 months of therapy. Am J Hypertens 2006;
19:1150–1155 © 2006 American Journal of Hypertension,
Ltd.
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arterial hypertension.L eft ventricular hypertrophy (LVH) is a hypertensivetarget organ damage and an independent cardiovas-cular risk factor.1–3 Importantly, LVH occurs not
only in severe but also in mild hypertension.4–7 In outpa-
tients with mild definite hypertension LVH is encountered
in up to 38% of patients.1
Most outpatients with newly diagnosed hypertension
have mild hypertension. Identifying hypertensive target
organ damage is important for early treatment stratifica-
tion. According to current guidelines,8–10 patients with
mild hypertension and LVH should receive immediate
drug treatment. Antihypertensive drug treatment reduces
left ventricular mass (LVM),11–16 and regression of LVH
is associated with reduced cardiovascular risk.11,13 Angio-
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Clinical Epidemiology, University Hospital Basel, Basel, Switzer-tensin II receptor antagonist therapy is more effective in
reducing LVM than -adrenergic receptor therapy.12 The
Losartan Intervention for Endpoint (LIFE) Reduction in
Hypertension Study trial demonstrated the superiority of
the angiotensin II receptor antagonist losartan compared to
atenolol in reducing cardiovascular end points in hyperten-
sive patients with electrocardiographic13 and echocardio-
graphic LVH.17
Although the value of baseline echocardiography for
LVH detection4–7,18,19 and risk stratification4,7,18,19 in hy-
pertensive patients has clearly been demonstrated, per-
forming baseline echocardiography for detection of LVH
in patients with newly detected hypertension is not rec-
ommended in current guidelines.8–10 Thus, the presence of
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sion.4,7,18,19
To our knowledge there are no randomized outcome
studies evaluating the impact of baseline echocardiogra-
phy on treatment outcomes in primary care patients with
newly detected essential hypertension. In this prospective
randomized trial, we evaluated the impact of baseline
echocardiography on LVM index and blood pressure (BP)
control in consecutive general medical outpatients from an
unselected primary care population with never-treated es-
sential hypertension.
Methods
Consecutive adult general medical outpatients (2615) were
screened for office hypertension.
All patients with elevated sitting office BP were
deemed eligible for the study (after 5 min of rest, mean of
two BP measurements 140/90 mm Hg at two different
visits, according to standard guidelines).8 Exclusion crite-
ria were pretreated hypertension, missing study participa-
tion consent, severe concomitant illness with the exception
of diabetes mellitus, and accepted indications for echocar-
diography (eg, pericarditis, heart failure, or the presence of
a heart murmur suggesting valvular heart disease). The
study protocol had been approved by the local ethics
committee.
The Medical Outpatient Department of the University
Hospital Basel, Switzerland, provides primary care for
general medical walk-in patients. Approximately 20% are
referred by general practitioners for second opinion or for
interdisciplinary ambulatory care. All patients are rou-
tinely seen by three- or four-year residents. They are
supervised by an attending physician in General Internal
Medicine.
Patients with newly detected office hypertension received
routine clinical work-up, according to standard guidelines8
(ie, history, physical examination, routine blood tests,
electrocardiogram [ECG] and urinalysis, and 24h ambula-
tory BP monitoring [24-h ABPM] with validated devices
[Spacelabs, Diessenhofen, Switzerland, and Mobilograph,
Stolberg, Germany]). Normal mean 24-h ABPM values
were defined as 130/80 mm Hg.
After having obtained informed written consent and
having ruled out white coat hypertension, patients with
definite hypertension were randomized by computer as to
make the result of the echocardiogram available to their
treating physician (echo group) or to withhold it (control
group).
Then all study patients underwent transthoracic echo-
cardiography with a HP 5500 system (Hewlett Packard,
Andover, MA) performed by one of two experienced
cardiologists who were instructed not to inform patients
about the echo findings. Both cardiologists were blinded to
the patients’ group allocation during the course of the
study. Only residents treating patients randomized to the
echo group, but not of patients randomized to the controlgroup, obtained a written report about the findings of
baseline echocardiography. Results of target organ dam-
age other than LVH were available for the treating physi-
cians of both groups.
Left ventricular mass index was calculated according to
the formula: 0.8  (1.04  [Interventricular septal thick-
ness  posterior wall thickness  enddiastolic diameter
(EDD)]3 EDD3) 0.6)/m2 body surface area. The LVH
was defined conservatively as LVM index 136 g/m2 for
men and110 g/m– for women, with sufficient sensitivity
to diagnose the more severe cases of LVH that are more
likely to change the routine treatment decision.
Area-based methods perform as well as height-based
methods for normalization of LVM mass for body size20
in populations with a low rate of obesity such as ours
(24%).
Treating residents received a written Joint National
Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC) VI guideline
summary as a general recommendation for antihyperten-
sive treatment decision. They based their treatment deci-
sion on the presence of hypertensive cardiac or renal target
organ damage. Specifically, renal target organ damage was
defined as microalbuminuria (albumin-to-creatinine ratio
2.26 mg/mmol) or proteinuria (protein-to-creatinine
ratio 11 mg/mmol), cardiac target organ damage as
having electrocardiographic signs of LVH (Sokolow-Lyon
index 3.5 mV or Cornell product 2440 mV  msec),
or an elevated LVM index in echocardiography (136
g/m2 for men and 110 g/m2 for women). When hyper-
tensive target organ damage was identified (LVH shown
by ECG or echocardiography, microalbuminuria, protein-
uria, diabetes mellitus, history of cardiovascular events),
drug treatment with angiotensin II receptor antagonist
therapy (particularly valsartan) was strongly encouraged.
In the course of the study, treating resident physicians
were free to adjust treatment if necessary. End of study
examinations including BP measurements and echocardi-
ography were performed after 6 months.
The primary outcome was the difference in mean LVM
index between the two groups. Secondary outcomes were
the comparison of mean differences in LVM index, office
and 24-h ABPM between the two groups, and the propor-
tion of patients with elevated LVM index in the two
groups after 6 months of therapy.
Descriptive statistics were calculated using two sample
test of proportions. We conducted analyses of covariance to
evaluate between group differences in LVM index at the end
of follow-up using baseline LVM index as a covariate,
and BP values at the end of follow-up using baseline BP
as a covariate. Primary analyses were performed on an
intention-to-treat basis. We used the last value carried-
forward method for missing values. In addition, we con-
ducted per protocol analyses for the primary outcomes
(LVM index and BP values after 6 months of follow-up)
to minimize potential masking of changes from baseline
that might occur with an intention-to-treat analysis. The
1152 AJH–November 2006–VOL. 19, NO. 11BASELINE ECHOCARDIOGRAPHY IN HYPERTENSIONpredefined level of significance was P  .05 (two-
sided). Statistical analyses were performed using Excel
5.0 (Microsoft, Redmond, WA) and Stata 8.0 (Stata Cor-
poration, College Station, TX) software.
The prevalence of echocardiographic LVH in mild-to-
moderate hypertensive patients is about 30%, whereas the
prevalence of electrocardiographic LVH is about 10%.1,18
In addition to the patients qualifying for angiotensin II
receptor antagonist therapy identified by echocardiogra-
phy and electrocardiography, we expected to identify an
additional 10% of patients with microalbuminuria, there-
fore a total of 40% of patients in the echo group and a total
of 20% of patients in the control group would be pre-
scribed angiotensin II receptor antagonist therapy. Based
on expected differences in regression of LVM index from
a randomized controlled trial comparing the effects of
valsartan and atenolol,15 and taking into consideration the
expected differences in prescription rates of angiotensin II
receptor antagonist therapy in both groups, the estimated
sample size of 91 patients in each group allowed us to
detect a difference in LVM index of 2 g/m2 between the
two groups after 6 months of therapy (power 0.8, two-
sided  0.05).
Results
Five hundred eighty of 2615 unselected consecutive med-
ical outpatients screened had an elevated first office BP
value; 207 had treated hypertension, 98 patients refused
participation, 48 patients were early dropouts or had nor-
mal second office BP values. A total of 227 patients with
newly detected office hypertension (according to JNC VI
definition) were included. Of the 227 patients examined,
50 (22%) had white coat hypertension and consequently
were not eligible for randomization. The remaining 177
(78%) patients had definite hypertension (defined as mean
24-h ABPM values 130/80 mm Hg) and were random-
Table 1. Baseline characteristics of patients with d
Mean age (y  SD)
Male
Mean BMI (kg/m2  SD)
Mean office blood pressure (mm Hg  SD)
Mean 24-h ambulatory blood pressure (mm Hg  SD
Mean LVM index (g/m2  SD)
Sokolow/Cornell index/product positive* (%)
Elevated LVM index† (%)
Relative wall thickness‡ (mean  SD)
Prevalent concentric geometry§ (%)
Isolated microalbuminuria (%)
Proteinuria (%)
Patients with target organ damage at baseline (%)
* Sokolow index positive: 35 mV or Cornell product positive 24
end-diastolic posterior wall thickness/end-diastolic LV internal diamete
echocardiographic LVH whose echocardiographic results were not commized into the echo group (n  91) and control group (n 
86). Of these 177 patients, 43 (24%) were obese, 9 had
diabetes mellitus, and 6 had a history of cardiovascular
disease. Echocardiographic imaging quality was very good.
Fewer than 10% of examinations had limited image qual-
ity. However, even in these patients, standard M-mode
dimensions for LVM could still be sufficiently determined.
Prevalence of
Hypertensive Target Organ Damage
The overall prevalence of echocardiographic LVH in
both groups was 29%. Seven patients (4%) had isolated
microalbuminuria, and 67 patients (38%) had protein-
uria. Hypertensive target organ damage was diagnosed
in 58 of 91 (64%) patients in the echo group and in 42
of 86 (49%) patients in the control group, based on
results of baseline diagnostic tests made available to the
treating physician (P  .04). An additional 5 patients
(6%) in the control group had LVH on echocardiogra-
phy only, and thus were missed as patients at higher risk
for cardiovascular complications. Baseline characteris-
tics, as well as data on LVM and geometry are given in
Table 1.
Proportion of Patients
Receiving Angiotensin II
Receptor Antagonist Therapy
In the echo group, 41 of 91 patients (45%) received
angiotensin II receptor antagonist therapy, compared to 27
of 86 patients (31%) in the control group (difference 14%,
95% CI 0–28%).
Ten of 91 patients (11%) in the echo group had echo-
cardiographic LVH without any other signs of hyperten-
sive target organ damage. Nine of these 10 patients were
prescribed angiotensin II receptor antagonist therapy. The
treatment allocation for angiotensin II receptor antagonist
ite hypertension (n  177)
Echo group
n  91
Control group
n  86 P
51 (13) 52 (14) .6
51 (56) 55 (64) .7
28.0 (5) 26.9 (5) .14
164(16)/101(9) 161(12)/101(9) .16/1.0
138(8)/87(7) 139(10)/85(6) .5/0.04
111.3 (28) 112.4 (27) .8
18 (20) 12 (14) .3
29 (32) 22 (26) .4
0.49 (0.09) 0.50 (0.09) .56
47 54 .17
3 (3) 4 (4) .6
36 (40) 31 (36) .6
58 (64) 47 (55) .22
V  msec; † 136 g/m2 for men and 110 g/m2 for women; ‡ 2xefin
)
40 m
r; § Relative wall thickness 0.43;  Including five patients with
unicated to the treating physician.
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groups is shown in Table 2.
Physicians Compliance
With Recommendation to
Prescribe Angiotensin II
Receptor Antagonist Therapy in
the Presence of Target Organ Damage
In the echo group, 18 of 58 patients (31%) did not receive
angiotensin II receptor antagonist therapy according to
guidelines in the presence of target organ damage as
compared to 23 of 42 patients (55%) in the control group
(difference 24%, 95% CI 5%–43%).
Of the 18 patients in the echo group not receiving
treatment according to guidelines with an angiotensin II
receptor antagonist, 9 had pathologic urine analysis, 6 had
electrocardiographic LVH, and 3 had echocardiographic
LVH with pathologic urine analysis. Hence, 3 of 29 pa-
tients with echocardiographic LVH in the echo group did
not receive angiotensin II receptor antagonist therapy. All
of them had mild hypertension and borderline elevation of
LVM index (mean 5 g/m2 above cutoff), and were pre-
scribed nondrug treatment. Thus, treatment allocation to
angiotensin II receptor antagonist therapy in the presence
of echocardiographic LVH was 90% (26 of 29 patients
with echocardiographic LVH).
Of the 23 patients in the control group not receiving
recommended treatment with an angiotensin II receptor
antagonist, 16 had isolated pathologic urine analysis, 5
Table 2. Treatment allocation at baseline
Echo
group
n  91
Control
group
n  86 P
Angiotensin II
antagonists (%) 41 (45) 27 (31) .06
Nondrug treatment
only (%) 32 (35) 39 (45) .17
-blockers (%) 6 (7) 6 (7) .9
Calcium antagonists (%) 3 (3) 2 (2) .7
Diuretics (%) 9 (10) 11 (13) .5
ACE inhibitor 0 1 1.0
Table 3. Left ventricular mass index (g/m2), mea
after 6 months
Left ventricular mass index
Prevalent concentric geometry‡ (%)
Systolic office blood pressure (mm Hg)
Diastolic office blood pressure (mm Hg)
Mean 24-h systolic blood pressure (mm Hg)
Mean 24-h diastolic blood pressure (mm Hg)* After adjustment for differences in baseline left ventricular mass index;
end-diastolic posterior wall thickness/end-diastolic LV internal diameterisolated electrocardiographic LVH, and 2 combined patho-
logic urine analysis and electrocardiographic LVH.
Six-Month Follow-Up Results
After 6 months, follow-up information was available for
74 patients in the echo group (81%) and from 71 patients
in the control group (83%).
There was no difference in LVM index or relative wall
thickness between the two groups (Table 3). Similarly,
there was no difference in systolic and diastolic office BP
between the two groups after 6 months of follow-up. Mean
systolic 24-h ABPM was higher in the echo group than in
the control group, whereas there was no statistically sig-
nificant difference in mean diastolic 24-h ABPM between
the two groups.
After 6 months of follow-up, 19 of 29 (66%) patients in
the echo group compared to 14 of 22 patients (64%) in the
control group had persistent elevated LVM index on echo-
cardiography (difference 2%, 95% CI 2% to 3%).
Results of all analyses performed after a follow-up of 6
months were not different when repeated on a per protocol
basis.
Discussion
In our trial, more newly detected hypertensive patients
with target organ damage compared to a control group
without the available information on baseline echocardi-
ography were identified, but this was not associated with a
reduction in LVM index or improved BP control.
The lack of difference in LVM index between the two
groups may have several reasons. Mean systolic 24-h ABPM
at the end of the trial was lower in the control group than in
the echo group (130  10 v 133  10 mm Hg, P  .05).
Blood pressure reduction by itself leads to a reduction in
LVM, independent of the antihypertensive agent used.
Therefore, the observed difference in mean systolic 24-h
ABPM, in favor of the control group, may have masked a
beneficial effect on LVM in the echo group. Furthermore,
most patients with LVH had borderline elevated LVM
index and therefore, any expected benefit on regression of
LVM was smaller than in patients who have markedly
elevated LVM.
fice, and 24-h ambulatory blood pressure (mm Hg)
cho group Control group P
106  21 106  23 .9*
69 75 .25
141  15 142  16 .5†
88  10 89  8 .3†
133  12 130  10 .05†
83  7 81  8 .11†n of
E† After adjustment for differences in baseline blood pressure; ‡ 2x
0.43.
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age in both groups to evaluate the impact of echocardio-
graphic evidence of LVH in addition to the impact of BP
measurements, ECG and extracardiac evidence of target
organ damage on treatment outcomes. To our knowledge,
this is the first randomized trial to examine the effect of
baseline echocardiography on antihypertensive treatment
decision and treatment outcomes in newly detected hyper-
tensive patients. We studied unselected primary care walk-in
patients who were obviously more likely to have mild hy-
pertension leading to an excellent generalizability for a
primary care population. Physicians performing echocar-
diography on patients assigned to the control group were
instructed not to inform patients about the results to keep
the patients blinded as to the results. In addition, doctors
performing 6-month follow-up examinations were fully
blinded to the patients’ group assignment to enhance the
internal validity of this trial. Participating physicians com-
plied well with the trial’s recommendation to prescribe
angiotensin II receptor antagonist therapy in case of echo-
cardiographically documented LVH in the echo group
(90% of patients with echocardiographic LVH were pre-
scribed angiotensin II receptor antagonists, particularly
valsartan).
The trial has several limitations. Results of 6-month
follow-up examinations were available from only about
82% of the original trial population. Dropout rate was
relatively high, because our patients were unselected younger
walk-in outpatients with a high percentage of migration. By
performing an intention-to-treat analysis using the last
value carried-forward method for missing values, we
might have introduced a bias in favor of the control group
by underestimating potential treatment benefits on LVM
index and BP in the echo group. However, the results of
the analyses did not qualitatively change when repeated on
per protocol analyses. There were no appreciable differ-
ences regarding age, gender, and baseline LVM between
patients with complete follow-up compared to the entire
study population.
Six months is a rather short period to evaluate treat-
ment-induced LVM changes; however, first significant
treatment-induced changes in LVM are observed after 6
months.12
We chose relatively high cutoff values to predefine
LVH. Lower cutoff values for LVH might have yielded a
higher LVH prevalence of predominantly borderline LVH
with possibly more aggressive treatments and possibly a
better outcome regarding LVM reduction.
The prevalence of target organ damage other than echo-
cardiographic LV hypertrophy at baseline was higher in
the echo group, although not significantly. As a result,
theoretically, it could be expected that target organ dam-
age is detected more often, leading to a bias in favor of the
echo group. Significantly more patients in the control
group compared to the echo group did not receive the
recommended treatment with an angiotensin II receptor
antagonist in the presence of target organ damage (55% v31%, P .02). This may lead to a bias in favor of the echo
group. The absence of any therapeutic benefit in the echo
group despite a significantly better adherence to the trial’s
recommendation to use angiotensin II receptor antagonists
in the presence of target organ damage supports the trial’s
conclusion that baseline echocardiography does not im-
prove LVM index or BP control in patients with newly
detected hypertension.
The absence of any improvement of LVM index and
BP control may be a consequence of recommending
monotherapy with an angiotensin II receptor antagonist in
the presence of target organ damage. It is still possible that
the recommendation of combined angiotensin II receptor
antagonist and diuretic therapy or other treatment, such as
angiotensin-converting enzyme inhibitors with or without
with diuretics, based on baseline echocardiographic infor-
mation may yield more beneficial changes in LVM index
and BP control.
The main outcomes examined in this trial are interme-
diate end points. The trial focused on the impact of echo-
cardiography without specific hypertensiologic supervision
of the treating physicians, and was not powered to look at
cardiovascular complications. We can therefore not com-
pletely rule out a potential benefit of baseline echocardiog-
raphy on cardiovascular outcomes. However, the absence of
any reduction in LVM and the absence of any improved
BP control in patients randomized to the echo group
markedly reduces the likelihood of any cardiovascular
benefit in this group.
We conclude that knowledge about baseline echocar-
diography leads to a higher rate of identification of hyper-
tensive target organ damage, but is not necessarily
associated with a reduction in LVM index or improved BP
control.
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